G1 Therapeutics buy thn
Start price
04.01.21
/
70%
€14.56
Target price
04.01.22
€28.00
Performance (%)
-11.23%
End price
05.09.21
€12.93
Summary
This prediction ended on 05.09.21 with a price of €12.93. The price of G1 Therapeutics has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.23%. thn has 70% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| G1 Therapeutics | -5.852% | -5.852% | 60.893% | -80.865% |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by thn for this prediction
In the thread G1 Therapeutics diskutieren
Buy mit Kursziel 28,0